Dr. Stange is founder and CEO of the Silversky group. His expertise in corporate financing is derived from his longstanding position as a consultant at McKinsey and Droege Comp. As interim managing director of numerous medtech and diagnostics companies, he also has a proven track record in successfully securing risk capital and business building.

As an active partner at Ventac Partners between 2008 and 2017, Dr. Stange founded and ran the German office of this pharma-focused life science consultancy. During this engagement, he advised many well-known companies in the area of corporate finance. In order to expand the strong focus of the German team on clients within the medtech, diagnostics and drug screening fields, business activities of the non-pharma Silversky group were merged as independent consulations. Since then, Silversky Life Sciences supports national and international startups in the search for risk and growth capital, as well as in the acquisition of public and private funding. Various German medium-sized companies also trust Silversky’s advice in the development of growth strategies, including buy and build concepts.

Although the Silversky group operates as an independent consultancy, it retains links with Ventac Partners through common portfolio customers and the active role of CEO Dr. Stange as a Ventac Holding shareholder.

Mirko Stange gained a PhD in Biochemistry and Biophysics with a focus on cardiovascular diseases from the University of North Carolina at Chapel Hill, USA and a diploma in chemistry from the Heinrich Heine University Dusseldorf.